Free Access
Med Sci (Paris)
Volume 32, Number 2, Février 2016
Page(s) 156 - 158
Section Nouvelles
Published online 02 March 2016
  1. Vincent QB, Ardant MF, Adeye A, et al. Clinical epidemiology of laboratory-confirmed Buruli ulcer in Benin: a cohort study. Lancet Glob Health 2014 ; 2 : e422–e430. [CrossRef] [PubMed] [Google Scholar]
  2. Williamson HR, Mosi L, Donnell R, et al. Mycobacterium ulcerans fails to infect through skin abrasions in a guinea pig infection model: implications for transmission. PLoS Negl Trop Dis 2014 ; 8 : e2770. [CrossRef] [PubMed] [Google Scholar]
  3. Asiedu K, Sherpbier R, Raviglione MC. Buruli ulcer Mycobacterium ulcerans infection. WHO Global Buruli Ulcer initiative. Report 2000. Geneva (Switzerland) : World Health Organisation, 2000. [Google Scholar]
  4. George KM, Chatterjee D, Gunawardana G, et al. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 1999 ; 283 : 854–857. [CrossRef] [PubMed] [Google Scholar]
  5. Fraga AG, Cruz A, Martins TG, et al. Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression. Infect Immun 2010 ; 79 : 421–430. [CrossRef] [PubMed] [Google Scholar]
  6. Torrado E, Adusumilli S, Fraga AG, et al. Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect Immun 2007 ; 75 : 3979–3988. [CrossRef] [PubMed] [Google Scholar]
  7. En J, Ishii N, Goto M. Role of mycolactone in the nerve damage of Buruli ulcer (Mycobacterium ulcerans infection). Nihon Hansenbyo Gakkai Zasshi 2011 ; 80 : 5–10. [CrossRef] [PubMed] [Google Scholar]
  8. Goto M, Nakanaga K, Aung T, et al. Nerve damage in Mycobacterium ulcerans-infected mice: probable cause of painlessness in buruli ulcer. Am J Pathol 2006 ; 168 : 805–811. [CrossRef] [PubMed] [Google Scholar]
  9. Marion E, Song OR, Christophe T, et al. Mycobacterial toxin induces analgesia in buruli ulcer by targeting the angiotensin pathways. Cell 2014 ; 157 : 1565–1576. [CrossRef] [PubMed] [Google Scholar]
  10. Rice AS, Dworkin RH, McCarthy TD, et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 2014 ; 383 : 1637–1647. [CrossRef] [PubMed] [Google Scholar]
  11. Mabèrou Houngbédji G, Frenette J. L’ulcère de Buruli. Med Sci (Paris) 2011 ; 27 : 187–192. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  12. Marsollier L, Aubry J, Milon G, Brodin P. Punaises aquatiques et transmission de Mycobacterium ulcerans. Med Sci (Paris) 2007 ; 23 : 572–575. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.